MedTrace Logo

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

NCT04965675 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 285

Last updated 2026-05-13

No results posted yet for this study

Summary

To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.

Conditions

  • Chronic Migraine in Children

Interventions

DRUG

Eptinezumab

Eptinezumab will be administered per dose and schedule specified in the arm.

DRUG

Placebo

Placebo matching to eptinezumab will be administered per schedule specified in the arm.

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

  • Email contact via H. Lundbeck A/S · H. Lundbeck A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2026-09-05
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Canada
  • Italy
  • Mexico
  • Poland
  • Portugal
  • Serbia
  • Spain
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04965675 on ClinicalTrials.gov